Janux Therapeutics Stock Soars on Report of Possible Sale to Big Pharma
-
Janux Therapeutics stock soared nearly 12% on Wednesday following a report that the clinical-stage biotech is considering a possible sale.
-
Janux is developing "T-cell engagers" to harness the immune system to fight cancer, and recent trial results were very encouraging.
-
The company has reportedly retained a financial advisor to evaluate options, including acquisition offers from larger pharmaceutical firms.
-
A sale could give a buyer quick access to Janux's promising investigational cancer therapies.
-
Janux has not commented publicly on the sale report, but it's believable given Big Pharma's appetite for oncology assets.